Higher Anaphylaxis Rates After HPV Vaccination in Australia
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Higher Anaphylaxis Rates After HPV Vaccination in Australia

OTTAWA, Ontario -- September 2, 2008 -- The estimated rate of anaphylaxis in young women after human papillomavirus (HPV) vaccination was 5 to 20 times higher than that identified in comparable school-based vaccination programs, according to a study published in the Canadian Medical Association Journal.

However, the overall rates of anaphylaxis were low with no associated serious lasting effects.

In a study of 114,000 women, a team of Australian researchers found 12 suspected cases of anaphylaxis, and confirmed 8 of these, in a 2007 vaccination program in New South Wales, Australia. Symptoms included difficulty breathing, nausea, and rashes.

Dr. Julia Brotherton, MD, National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, Westmead, New South Wales, Australia, and colleagues postulate that reasons for an increased rate of anaphylaxis may include possible allergic reaction to the vaccine components, enhanced adverse event surveillance, higher rates of anaphylaxis in women from mid-adolescence compared with men, and an apparent increase in incidence of anaphylaxis in Australia.

The estimated rate of anaphylaxis following HPV vaccination was 2.6 per 100,000 doses administered compared with a rate 0.1 per 100 000 doses administered in a 2003 school-based meningococcal C vaccination program.

HPV vaccination programs will begin this fall in the United Kingdom and other European countries as well as in parts of Canada and the United States.

Dr. Brotherton stresses "the importance of good training for staff administering vaccines in school or other settings in the recognition and management of suspected anaphylaxis and its reporting." They conclude that anaphylaxis following the HPV vaccine is rare and vaccine programs should continue.

SOURCE: Canadian Medical Association Journal

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities